Autore: Luca Cirillo
Relatore: Daniela Taverna
Università: Università degli Studi di Torino
Facoltà: Facoltà di Scienze Matematiche, Fisiche e Naturali
Corso: Laurea Magistrale in Biologia Cellulare e Molecolare
Data di Discussione: 18/07/2014
Voto: 110 cum laude
Disciplina: Biologia molecolare avanzata
Tipo di Tesi: Sperimentale
Altri Relatori: Prof. Maria Flavia Di Renzo
Grande Area: Area Scientifica
Dignità di Stampa: Si
In Collaborazione con: IRCC - Candiolo
Settori Interessati: Biologia, Medicina, Ricerca
Cisplatin is a powerful anticancer drug, used in the treatment of many tumors since 1970. The mechanism of action is based on adducts formation in DNA strands, platinum-based chemotherapy is widely used to treat various kinds of cancer, but many patients ultimately relapse due to drug resistance. Moreover the feasibility of the treatment is often limited by the severe side effects that prevent the use of effective concentration of platinum drugs. Therefore, to find a strategy to lower the concentration of platinum in therapy and to develop a method to overcome resistance is crucial in modern research.
In the laboratory where I worked for my thesis project phosphoproteomic data had been obtained with SILAC technology, in order to identify kinases induced or repressed by cisplatin treatment in the ovarian cancer cell line SK-OV-3. PIM2 was identified among kinases likely to be involved, and came out to be the most interesting not only because its role in CDDP response of ovarian cancer ...